Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction

Authors: Robinson, Jennifer G; Davidson, Michael H

Source: Expert Review of Cardiovascular Therapy, Volume 4, Number 4, July 2006 , pp. 461-476(16)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

A low-density lipoprotein (LDL) cholesterol goal of less than 100 mg/dl is recommended for patients at moderate to high risk of cardiovascular disease with an optional LDL goal of less than 70 mg/dl for patients at a very high risk of cardiovascular disease. Most patients will require reductions in LDL of more than 50% in order to achieve these more aggressive goals. Only a few agents will lower LDL by at least 50%. This review will focus on the efficacy and safety ezetimibe/simvastatin coadministered as a therapy with enhanced LDL-lowering efficacy, while minimizing the adverse effects of statins in a wide range of patients. Ezetimibe 10 mg/simvastatin 80 mg lowers LDL by approximately 60% and has been demonstrated to be superior to the highest doses of atorvastatin and rosuvastatin for lowering LDL and raising high-density lipoprotein.

Keywords: cardiovascular disease; cholesterol absorption; ezetimibe; lipids; risk reduction; statin

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14779072.4.4.461

Publication date: 2006-07-01

More about this publication?

Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites